ORPHEUS BIOSCIENCE

Orpheus is a privately held biotechnology company with research facilities in Northern Virginia, USA. Orpheus' dedicated and experienced management and scientific team are committed to commercializing PR1P for the treatment of ROP and other ocular indications. PR1P and related peptides are patent protected in both composition and utilization... Orpheus is focused on providing a treatment for retinopathy of prematurity (ROP), a potentially blinding affliction that occurs in premature neonates. To this end, Orpheus is developing a novel peptide therapeutic, PR1P, that targets a critical mediator of ROP, vascular endothelial growth factor (VEGF). By binding to and stabilizing VEGF, PR1P can prevent the harmful retinal vascular anomalies that occur as premature neonates receive required respiratory support and oxygen supplementation. PR1P has the potential to prevent the development of ROP before retinal damage occurs in these newborns. This makes PR1P the FIRST preventative treatment for..

Also known as: Orpheus, Orpheus BioScience, LLC